Correction

Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors (vol 11, e006348, 2023)

Journal

JOURNAL FOR IMMUNOTHERAPY OF CANCER
Volume 11, Issue 7, Pages -

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/jitc-2022-006348corr1

Keywords

-

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Recommended

No Data Available
No Data Available